TY  - JOUR
AU  - Wilson, D
AU  - Seiffge, DJ
AU  - Traenka, C
AU  - Basir, G
AU  - Purrucker, JC
AU  - Rizos, T
AU  - Sobowale, OA
AU  - Sallinen, H
AU  - Yeh, S-J
AU  - Wu, TY
AU  - Ferrigno, M
AU  - Houben, R
AU  - Schreuder, FHBM
AU  - Perry, LA
AU  - Tanaka, J
AU  - Boulanger, M
AU  - Salman, RA-S
AU  - Jaeger, HR
AU  - Ambler, G
AU  - Shakeshaft, C
AU  - Yakushiji, Y
AU  - Choi, PMC
AU  - Staals, J
AU  - Cordonnier, C
AU  - Jeng, J-S
AU  - Veltkamp, R
AU  - Dowlatshahi, D
AU  - Engelter, ST
AU  - Parry-Jones, AR
AU  - Meretoja, A
AU  - Werring, DJ
Y2  - 2021/02/04
Y1  - 2017/05/02
SN  - 0028-3878
UR  - http://hdl.handle.net/11343/259042
AB  - OBJECTIVE: In an international collaborative multicenter pooled analysis, we compared mortality, functional outcome, intracerebral hemorrhage (ICH) volume, and hematoma expansion (HE) between non-vitamin K antagonist oral anticoagulation-related ICH (NOAC-ICH) and vitamin K antagonist-associated ICH (VKA-ICH). METHODS: We compared all-cause mortality within 90 days for NOAC-ICH and VKA-ICH using a Cox proportional hazards model adjusted for age; sex; baseline Glasgow Coma Scale score, ICH location, and log volume; intraventricular hemorrhage volume; and intracranial surgery. We addressed heterogeneity using a shared frailty term. Good functional outcome was defined as discharge modified Rankin Scale score ≤2 and investigated in multivariable logistic regression. ICH volume was measured by ABC/2 or a semiautomated planimetric method. HE was defined as an ICH volume increase >33% or >6 mL from baseline within 72 hours. RESULTS: We included 500 patients (97 NOAC-ICH and 403 VKA-ICH). Median baseline ICH volume was 14.4 mL (interquartile range [IQR] 3.6-38.4) for NOAC-ICH vs 10.6 mL (IQR 4.0-27.9) for VKA-ICH (p = 0.78). We did not find any difference between NOAC-ICH and VKA-ICH for all-cause mortality within 90 days (33% for NOAC-ICH vs 31% for VKA-ICH [p = 0.64]; adjusted Cox hazard ratio (for NOAC-ICH vs VKA-ICH) 0.93 [95% confidence interval (CI) 0.52-1.64] [p = 0.79]), the rate of HE (NOAC-ICH n = 29/48 [40%] vs VKA-ICH n = 93/140 [34%] [p = 0.45]), or functional outcome at hospital discharge (NOAC-ICH vs VKA-ICH odds ratio 0.47; 95% CI 0.18-1.19 [p = 0.11]). CONCLUSIONS: In our international collaborative multicenter pooled analysis, baseline ICH volume, hematoma expansion, 90-day mortality, and functional outcome were similar following NOAC-ICH and VKA-ICH.
LA  - English
PB  - LIPPINCOTT WILLIAMS & WILKINS
T1  - Outcome of intracerebral hemorrhage associated with different oral anticoagulants
DO  - 10.1212/WNL.0000000000003886
IS  - Neurology
VL  - 88
IS  - 18
SP  - 1693-1700
L1  - /bitstream/handle/11343/259042/PMC5409844.pdf?sequence=1&isAllowed=y
ER  -